
Jagsonpal Pharmaceuticals Ltd Sees Bullish Momentum Shift Amid Strong Technical Signals
2026-09-25 08:00:19Jagsonpal Pharmaceuticals Ltd has demonstrated a significant shift in price momentum, with technical indicators signalling a bullish trend reversal. The stock’s recent 7.95% daily gain and upgrades in technical grades reflect growing investor confidence amid a broader market environment that remains challenging.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Hold
2026-09-22 10:10:03Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 22 September 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Hold
2026-09-11 10:10:05Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-09-08 08:00:27Jagsonpal Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early September 2026. Despite a slight dip in daily price, key indicators such as MACD and moving averages continue to support a cautiously optimistic outlook, while other metrics suggest a more tempered trend. This article analyses the recent technical developments and their implications for investors in the pharmaceuticals and biotechnology sector.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Hold
2026-08-31 10:10:04Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 31 August 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Hold
2026-08-20 10:10:05Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 August 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Hold
2026-08-09 10:10:04Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-08-03 08:00:17Jagsonpal Pharmaceuticals Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish to a more confident bullish trend. Despite a recent day decline of 2.68%, the stock’s underlying technical parameters suggest improving momentum that could influence investor sentiment in the coming weeks.
Read full news articleAre Jagsonpal Pharmaceuticals Ltd latest results good or bad?
2026-07-30 19:18:55Jagsonpal Pharmaceuticals Ltd has reported its financial results for Q1 FY27, showcasing notable operational trends. The company achieved a record quarterly revenue of ₹82.23 crores, reflecting a sequential growth of 28.08% compared to the previous quarter. Year-on-year revenue growth was recorded at 8.76%, indicating steady market expansion despite competitive pressures. Net profit for the quarter stood at ₹13.19 crores, which represents a significant quarter-on-quarter increase of 50.56% and a year-on-year growth of 22.13%. The improvement in profitability is further underscored by an operating margin that expanded to 20.97%, up from 17.38% in the previous quarter, highlighting effective cost management and a favorable product mix. The company's return on equity (ROE) is reported at 17.66%, which is above its five-year average, suggesting effective management in generating returns for shareholders. Addi...
Read full news articleAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
23-Sep-2026 | Source : BSEPress Release on Acquisition of Wellness Portfolio of Group pharmaceuticals Limited
Announcement under Regulation 30 (LODR)-Acquisition
23-Sep-2026 | Source : BSEAcquisition of the Wellness Portfolio of Group Pharmaceuticals Limited.
Shareholder Meeting / Postal Ballot-Scrutinizers Report
21-Sep-2026 | Source : BSEVoting Result and scrutinizer Report of 47th Annual General Meeting.
Corporate Actions
No Upcoming Board Meetings
Jagsonpal Pharmaceuticals Ltd has declared 200% dividend, ex-date: 04 Sep 26
Jagsonpal Pharmaceuticals Ltd has announced 2:5 stock split, ex-date: 08 Jan 25
No Bonus history available
No Rights history available






